Press release · 19 Nov 2026

Long-Acting Injectable Pharmaceuticals Market Size & Forecast to 2035

Published: 19 Nov 2026 | Forecast Coverage: 2026–2035 | Base Year: 2025 | Format: PDF | Publisher: Vectomat Insights

Author: Sneha ReddyReviewed by: Sunil BhosaleFact CheckedPublished:

Long-Acting Injectable Pharmaceuticals Market by Product Type (Microspheres, In-Situ Forming Depots/Gels, Implants, Suspensions), by Therapeutic Area (Psychiatric Disorders, Contraception, Oncology, Infectious Disease, Ophthalmology, endocrinology and metabolic disease), by Technology (PLGA-Based, Non-PLGA Polymer-Based, Non-Polymeric (Implant), Oil-based depot and crystal suspension technologies), by End User (Hospitals, Specialty Pharmacies, Homecare Settings, Correctional & Public Health Facilities), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035

St. Catharines, Ontario, 19 Nov 2026 — Vectomat Insights has published a new report titled ‘Long-Acting Injectable Pharmaceuticals Market by Product Type, Therapeutic Area, Technology, End User, and Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035.’ The Global Long-Acting Injectable Pharmaceuticals Market was valued at USD 12,642.7 Mn in 2025 and is projected to reach USD 35,129.3 Mn by 2035, growing at a CAGR of 10.76% during the forecast period 2026–2035, according to Vectomat Insights.

Microspheres lead product types with 32.0% of 2025 revenue, but implants are the growth engine at a 15.1% CAGR, and North America takes 39.0% of global sales on the back of approvals such as Gilead's twice-yearly Yeztugo and Organon's five-year NEXPLANON label.

The Global Long-Acting Injectable Pharmaceuticals market was valued at USD 12,642.7 Mn in 2025 and is projected to reach USD 35,129.3 Mn by 2035, growing at a 10.76% CAGR, according to Vectomat Insights. North America leads with 39.0% of revenue, microspheres are the largest product type at 32.0%, and implants grow fastest at 15.1% a year.

Key Insights Snapshot

MetricValue
Report TitleGlobal Long-Acting Injectable Pharmaceuticals Market Size, Share, Growth & Forecast By Product Type, Therapeutic Area, Technology, and End User, 2026–2035
Base Year Market SizeUSD 12,642.7 Mn (2025)
Forecast Market SizeUSD 35,129.3 Mn (2035)
CAGR10.76%
Forecast Period2026–2035
Dominant RegionNorth America (39.0%)
Fastest-Growing RegionAsia Pacific
Dominant SegmentMicrospheres (32.0%)
Dominant ApplicationPsychiatric Disorders
Report FormatPDF
PublisherVectomat Insights

What Pharmaceutical Leaders Need to Know About the Long-Acting Injectable Pharmaceuticals Market

Pharma R&D Heads: Dosing interval is now the main axis of differentiation. Implants are forecast to grow at 15.1% a year to USD 11,348.3 Mn by 2035, so programs without a three-month-plus format risk being displaced by reformulated rivals.

Chief Medical Officers: Teva's October 2026 WELTRUZA approval removes post-injection monitoring from long-acting olanzapine. Psychiatric services can now start depots earlier, in a therapeutic pool worth USD 4,258.4 Mn in 2025.

Hospital Pharmacy Directors: Hospitals already administer 43.7% of long-acting revenue, and that share is set to grow at 13.54% a year. Storage, observation space and REMS training budgets need to rise with it this planning cycle.

Business Development Leads: Platform deals are the fastest route into the category. Camurus's June 2025 Lilly agreement and Lupin's October 2025 PrecisionSphere program show partners pay for delivery technology before the molecule is chosen.

Market Access Directors: Twice-yearly HIV prevention launched at about USD 28,000 a year in the U.S., while generic lenacapavir arrives at about USD 40 a year in 2027. Tiered pricing is now the expected model, and payers will benchmark against it.

Long-Acting Injectable Pharmaceuticals market at a glance — USD 12,642.7 Mn (2025), 10.76% CAGR | Vectomat Insights
Key numbers for the Global Long-Acting Injectable Pharmaceuticals market: size, growth, leading segments, regions and companies. Source: Vectomat Insights, Long-Acting Injectable Pharmaceuticals Market Report.

What Is the Long-Acting Injectable Pharmaceuticals Market?

Long-Acting Injectable Pharmaceuticals Market refers to drugs formulated to release over weeks, months or years from a single injection or implant, replacing daily pills or frequent shots. The case for them has never been stronger. Fewer than one in five young patients with first-episode psychosis stay on oral antipsychotics, and HIV prevention now has a twice-yearly option in Gilead's Yeztugo. Payers that once treated depots as a niche now see them as a relapse and readmission tool. Vectomat Insights values the market at USD 12,642.7 Mn in 2025, rising to USD 35,129.3 Mn by 2035. The winners will be the companies that stretch the dosing interval furthest.

How Is the Long-Acting Injectable Pharmaceuticals Market Segmented?

Microspheres hold 32.0% of 2025 revenue, the largest product type, thanks to long-running PLGA brands like Lupron Depot and Vivitrol. But implants are where growth is: they're forecast to compound at 15.1% a year to USD 11,348.3 Mn by 2035. The January 2026 FDA decision giving Organon's NEXPLANON a five-year label shows why. By therapeutic area, psychiatric disorders lead at 33.7%, while ophthalmology, endocrinology and metabolic disease grows fastest at 16.46% a year. Hospitals administer 43.7% of all long-acting revenue.

This report segments the Long-Acting Injectable Pharmaceuticals market as follows:

  • By Product Type: Microspheres, In-Situ Forming Depots/Gels, Implants, Suspensions
  • By Therapeutic Area: Psychiatric Disorders, Contraception, Oncology, Infectious Disease, Ophthalmology, endocrinology and metabolic disease
  • By Technology: PLGA-Based, Non-PLGA Polymer-Based, Non-Polymeric (Implant), Oil-based depot and crystal suspension technologies
  • By End User: Hospitals, Specialty Pharmacies, Homecare Settings, Correctional & Public Health Facilities
  • By Region: North America, Europe, Asia Pacific, Latin America, The Middle East, Africa

Browse the full Long-Acting Injectable Pharmaceuticals Market report →

Long-acting injectables market size — USD 12,642.7 Mn (2025) to USD 35,129.3 Mn (2035) at 10.76% CAGR | Vectomat Insights
The Global Long-Acting Injectable Pharmaceuticals market grows from USD 12,642.7 Mn in 2025 to USD 35,129.3 Mn by 2035, a 10.76% CAGR. Source: Vectomat Insights, Long-Acting Injectable Pharmaceuticals Market Report.

Which Region Leads the Long-Acting Injectable Pharmaceuticals Market?

North America leads with 39.0% of 2025 revenue, worth USD 4,930.7 Mn, and the U.S. alone is a USD 3,944.6 Mn market. That's no accident: Yeztugo, CAMCEVI ETM, NEXPLANON's five-year label and WELTRUZA all cleared the FDA between June 2025 and October 2026. Europe holds 27.0%, with Germany at USD 955.8 Mn. Asia Pacific, at 23.0%, is the fastest-growing region, as South Korea expands at 13.0% a year and Japan at 11.1%. Latin America holds 5.0%, the Middle East 3.1% and Africa 2.9%, though Africa's dose volumes far exceed its revenue share.

Long-Acting Injectable Pharmaceuticals market share by region — North America leads with 39.0% in 2025 | Vectomat Insights
North America leads the Global Long-Acting Injectable Pharmaceuticals market with a 39.0% share in 2025, while Asia Pacific grows fastest. Source: Vectomat Insights, Long-Acting Injectable Pharmaceuticals Market Report.

Key Factors Propelling the Long-Acting Injectable Pharmaceuticals Market

Adherence Gaps in Serious Mental Illness — Fewer than 1 in 5 young people with first-episode psychosis stay adherent to antipsychotics, per a September 2026 Psychiatric Times report. That gap is why psychiatric disorders already take 33.7% of LAI revenue.

Twice-Yearly HIV Prevention Scale-Up — Gilead's Yeztugo became the first twice-yearly PrEP option in June 2025. The Global Fund and PEPFAR have each committed to reach up to 2 million people with it.

Longer Dosing Interval Approvals — Regulators keep approving longer intervals, from a five-year NEXPLANON label in January 2026 to a three-month CAMCEVI ETM in August 2025.

Long-Acting Obesity and Metabolic Pipelines — Pfizer bought monthly GLP-1 developer Metsera in November 2025, and Camurus signed a FluidCrystal incretin deal with Eli Lilly in June 2025.

This is a historic day in the decades-long fight against HIV.

— Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences · Press · Gilead Sciences press release, 18 Jun 2025 [source]

Key Headwinds Facing the Long-Acting Injectable Pharmaceuticals Market

Premium Pricing and Access Pushback — Yeztugo launched at a U.S. list price of about USD 28,000 a year, and UNAIDS publicly urged Gilead to cut it.

Complex Microsphere Manufacturing — Aseptic PLGA microsphere production is hard to scale, which is why so few generic microsphere products exist.

Provider Administration and REMS Burden — Most LAIs need a trained clinician, and NEXPLANON's five-year label came with a new REMS program in January 2026.

Even with these headwinds, the market is set to climb from USD 12,642.7 Mn in 2025 to USD 35,129.3 Mn by 2035.

What Industry Leaders Are Saying About the Long-Acting Injectable Pharmaceuticals Market

While an HIV vaccine remains elusive, lenacapavir is the next best thing: a long-acting antiretroviral shown in trials to prevent almost all HIV infections among those at risk.

— Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization · Press · WHO news release, 14 Jul 2025 [source]

Securing access to lenacapavir for up to two million people is a breakthrough for HIV prevention in low- and middle-income countries, even as global health funding comes under pressure.

— Peter Sands, Executive Director, The Global Fund · Press (paraphrased) · The Global Fund news release, 9 Jul 2025 [source]

Lenacapavir can only change the course of the HIV epidemic if it is affordable and available to everyone who needs it, so the price must come down and generic production must expand.

— Winnie Byanyima, Executive Director, UNAIDS · Press (paraphrased) · UNAIDS statement, 18 Jun 2025 [source]

Real-world data show our long-acting injectables deliver high effectiveness and adherence benefits for people living with HIV, which supports the move to ultra-long-acting regimens.

— Deborah Waterhouse, Chief Executive Officer, ViiV Healthcare · Press (paraphrased) · ViiV Healthcare / GSK press release, 8 Jul 2025 [source]

Report Segmentation & Scope

Vectomat Insights | Market & Reports — Report Segmentation & Scope
Scope Included in the Study
By Product Type
  • Microspheres
  • In-Situ Forming Depots/Gels
  • Implants
  • Suspensions
By Therapeutic Area
  • Psychiatric Disorders
  • Contraception
  • Oncology
  • Infectious Disease
  • Ophthalmology, endocrinology and metabolic disease
By Technology
  • PLGA-Based
  • Non-PLGA Polymer-Based
  • Non-Polymeric (Implant)
  • Oil-based depot and crystal suspension technologies
By End User
  • Hospitals
  • Specialty Pharmacies
  • Homecare Settings
  • Correctional & Public Health Facilities
Regional Analysis
North AmericaThe U.S., Canada, Mexico
EuropeGermany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe
Asia PacificChina, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific
Latin AmericaBrazil, Argentina, Colombia, Chile, Peru, Rest of Latin America
The Middle EastGCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East
AfricaSouth Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa
Note: The scope can be further tailored as per your specific requirement. Contact sales@vectomatinsights.com

Who Are the Leading Companies in the Long-Acting Injectable Pharmaceuticals Market?

Key players operating in the Global Long-Acting Injectable Pharmaceuticals market include Johnson & Johnson (U.S.), Otsuka Pharmaceutical (Japan), Teva Pharmaceuticals (Israel), Gilead Sciences (U.S.), ViiV Healthcare (U.K.), Pfizer (U.S.), Organon (U.S.), Alkermes (Ireland), Indivior (U.S.), Ipsen (France), Camurus (Sweden), Medincell (France), Foresee Pharmaceuticals (Taiwan) and Lupin (India), among others. Brand owners still hold the pricing power, but platform companies are where the new products come from: Medincell's copolymer technology sits behind Teva's Uzedy and WELTRUZA, and Camurus licenses its lipid depot to Eli Lilly. Expect more of that model, with dosing interval rather than molecule as the main competitive weapon.

Long-Acting Injectable Pharmaceuticals Market: Latest Industry Moves

June 2025 — Gilead Sciences: The FDA approved Yeztugo (lenacapavir), the first twice-yearly injectable option for HIV pre-exposure prophylaxis.

July 2025 — Camurus: The European Commission granted marketing authorisation for Oczyesa, a FluidCrystal octreotide subcutaneous depot, for acromegaly.

August 2025 — Foresee Pharmaceuticals: The FDA approved CAMCEVI ETM 21 mg, a ready-to-use three-month leuprolide mesylate depot for advanced prostate cancer.

October 2025 — Lupin: Lupin launched a strategic partnership program to open its PrecisionSphere long-acting microsphere platform to external developers.

January 2026 — Organon: The FDA approved a supplemental NDA extending NEXPLANON (etonogestrel implant 68 mg) use to five years, with a new REMS program.

October 2026 — Teva Pharmaceuticals: The FDA approved WELTRUZA, the first once-monthly subcutaneous olanzapine injectable for adults with schizophrenia, built on Medincell technology.

Frequently Asked Questions

What is the Long-Acting Injectable Pharmaceuticals market size and forecast?

The Global Long-Acting Injectable Pharmaceuticals market was valued at USD 12,642.7 Mn in 2025 and is forecast to reach USD 35,129.3 Mn by 2035, growing at a 10.76% CAGR during 2026–2035. North America leads with a 39.0% share, microspheres are the largest product type at 32.0% of revenue, and implants grow fastest at 15.1% a year, according to Vectomat Insights.

Which region dominates the Long-Acting Injectable Pharmaceuticals market?

North America dominates with 39.0% of 2025 revenue (USD 4,930.7 Mn), and the United States accounts for USD 3,944.6 Mn on the back of approvals such as Yeztugo, CAMCEVI ETM and WELTRUZA. Europe follows at 27.0%, led by Germany at USD 955.8 Mn. Asia Pacific is the fastest-growing region, with South Korea expanding at 13.0% a year, according to Vectomat Insights.

What are the key growth drivers of the Long-Acting Injectable Pharmaceuticals market?

Growth comes from poor adherence to oral antipsychotics, the rollout of twice-yearly HIV prevention backed by Global Fund and PEPFAR commitments for up to 2 million people each, regulatory approval of longer dosing intervals such as the five-year NEXPLANON label, and new monthly obesity and metabolic depots. Teva's October 2026 WELTRUZA approval and Pfizer's November 2025 Metsera acquisition show both psychiatry and obesity pulling in new investment, according to Vectomat Insights.

Who are the leading companies in the Long-Acting Injectable Pharmaceuticals market?

Leading companies include Johnson & Johnson, Otsuka Pharmaceutical, Teva Pharmaceuticals, Gilead Sciences, ViiV Healthcare, Pfizer, Organon, Alkermes, Indivior, Ipsen, Camurus, Medincell, Foresee Pharmaceuticals and Lupin. Brand owners hold most of the value, while platform companies such as Medincell and Camurus supply the delivery technology behind new launches. Competition increasingly turns on dosing interval rather than molecule, according to Vectomat Insights.

How is the Long-Acting Injectable Pharmaceuticals market segmented?

The market is segmented by Product Type (microspheres dominant at 32.0%; implants fastest-growing), by Therapeutic Area (psychiatric disorders dominant at 33.7%), by Technology (PLGA-based dominant at 47.4%), by End User (hospitals dominant at 43.7%), and by Region across six VMI geographies with the Middle East and Africa separate. Product-level data runs from 2023 to 2035, according to Vectomat Insights.

How can I access the full VMI Long-Acting Injectable Pharmaceuticals market report?

The full VMI Long-Acting Injectable Pharmaceuticals market report is available as a free sample, a full purchase or a custom inquiry through the Vectomat Insights website. For custom scope, such as additional molecules, countries or extended forecasts, contact sales@vectomatinsights.com and an analyst will respond. The sample previews segment tables and regional forecasts, according to Vectomat Insights.

Access the Complete Long-Acting Injectable Pharmaceuticals Market Report

300+ pages | Global coverage | PDF | 2026

Contact: sales@vectomatinsights.com

About Vectomat Insights

Vectomat Insights is an independent market research firm. Our analysts build every market model in-house, from company revenues, government and regulatory data, and interviews with industry participants, and each report is reviewed by a senior analyst and fact-checked before publication.

Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com · +1 416-876-0312